anti-cd38
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 2, 2022 (NCT06571864)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07090954 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Government of China |
| NCT06014775 | Phase 2 | Dec 31, 2023 | China Academy of Chinese Medical Sciences |
| NCT06168851 | Phase 2 | Dec 31, 2023 | China Academy of Chinese Medical Sciences |
| NCT05983952 | Phase 2 | Aug 31, 2023 | China Academy of Chinese Medical Sciences |
| NCT06571864 | N/A | Jan 2, 2022 | University of Turin |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| University of Turin | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1